1 2 3 4 5

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults

Tebas, Pablo; Spitsin, Sergei; Barrett, Jeffrey S.; More

AIDS . 29(8):931-939, May 15, 2015.

Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1...

Palella, Frank J. Jr; Fisher, Martin; Tebas, Pablo; More

AIDS . 28(3):335-344, January 28, 2014.

Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals

Tebas, Pablo; Frank, Ian; Lewis, Mark; More

AIDS . 24(14):2187-2192, September 10, 2010.

Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen

Fischl, Margaret A; Collier, Ann C; Mukherjee, A Lisa; More

AIDS . 21(3):325-333, January 30, 2007.

Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides

Dubé, Michael P; Parker, Robert A; Tebas, Pablo; More

AIDS . 19(16):1807-1818, November 4, 2005.

Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression

Havlir, Diane V.; Gilbert, Peter B.; Bennett, Kara; More

AIDS . 15(11):1379-1388, July 27, 2001.

Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients

Zhou, Xiao-Jian; Havlir, Diane V.; Richman, Douglas D.; More

AIDS . 14(18):2869-2876, December 22, 2000.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of...

Squires, Kathleen E.; Gulick, Roy; Tebas, Pablo; More

AIDS . 14(11):1591-1600, July 28, 2000.

1 2 3 4 5